Rhythm Pharmaceuticals
RYTM
85 hedge funds and large institutions have $970M invested in Rhythm Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 38 increasing their positions, 9 reducing their positions, and 4 closing their positions.
750% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 4
322% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 9
100% more capital invested
Capital invested by funds: $485M → $970M (+$485M)
55% more funds holding
Funds holding: 55 → 85 (+30)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
4.32% more ownership
Funds ownership: 89.3% → 93.63% (+4.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$42.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$32.7M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$18M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$16.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$22.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.34M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.06M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.58M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$2.15M |
RYTM Hedge Fund Activity: Q2 2018 in Review
85 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2018, worth a combined $970M — up 100% from $485M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new RYTM positions and 4 closed out — a net gain of 30 holders — while 38 added to existing stakes and 9 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $42.2M. The largest seller was OrbiMed, cutting an estimated $22.9M.
- 85 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2018, up from 55 in Q1 2018.
- Funds reported $970M of Rhythm Pharmaceuticals stock for Q2 2018, up 100% quarter-over-quarter.
- 34 funds opened new Rhythm Pharmaceuticals positions in Q2 2018 and 4 closed out, a net change of +30 holders.
- The largest Rhythm Pharmaceuticals buyer in Q2 2018 was RA Capital Management, an estimated $42.2M added.
- The largest Rhythm Pharmaceuticals seller in Q2 2018 was OrbiMed, an estimated $22.9M sold.
Based on aggregated 13F filings for Q2 2018.